Loading
Prostate Cancer Treatment and Research / Protease and Inhibitor Mechanisms / Ferroptosis and Cancer Prognosis · Journal article
Frontiers in Pharmacology · August 18, 2026
Raises a question worth testing. It does not answer one.
This is a computational and in vitro mechanistic study proposing that secretory leukocyte protease inhibitor (SLPI) is associated with androgen receptor pathway state and enzalutamide sensitivity in castration-resistant prostate cancer. SLPI overexpression suppressed proliferation and migration and enhanced enzalutamide-induced apoptosis in prostate cancer cell lines, and AR-pathway modulation reciprocally regulated SLPI expression; however, the authors acknowledge that protein-level, loss-of-function, in vivo, and clinically annotated validation are required before clinical relevance can be established.
Computational single-cell RNA-sequencing analysis with in vitro cell-line mechanistic studies. Computational: localized prostate cancer and metastatic CRPC samples from public single-cell dataset. In vitro: 22Rv1 and C4-2 castration-resistant prostate cancer cell lines compared to normal RWPE-1 cells.. Intervention: SLPI stable overexpression in prostate cancer cell lines; AR-pathway modulation (androgen deprivation, AR knockdown, DHT treatment, enzalutamide dosing).. Compared with: Normal RWPE-1 prostate epithelial cells; untreated and control-transduced cell lines; vehicle and standard androgen treatments..
SLPI expression was lower in prostate cancer cell lines (22Rv1 and C4-2) than in normal RWPE-1 cells SLPI overexpression suppressed proliferation, migration, and clonogenic growth in cell-line models Androgen deprivation and AR knockdown increased SLPI expression; DHT-mediated AR reactivation reduced SLPI expression
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
While the mechanistic findings are suggestive, clinicians should not currently use SLPI as a biomarker or therapeutic target outside research. The work identifies a hypothesis requiring substantial additional validation including protein-level confirmation, loss-of-function studies, animal models, and prospective patient cohort analysis before clinical translation.
Mechanistic study combining computational analysis of public single-cell data with in vitro cell-line models to propose SLPI as a putative response factor; lacks clinical validation, in vivo evidence, and the authors explicitly state further validation is required.
As stated by the source record.
Quoted from the source exactly as published.
While the mechanistic findings are suggestive, clinicians should not currently use SLPI as a biomarker or therapeutic target outside research. The work identifies a hypothesis requiring substantial additional validation including protein-level confirmation, loss-of-function studies, animal models, and prospective patient cohort analysis before clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Castration-resistant prostate cancer (CRPC) develops through tumor-cell plasticity, androgen receptor (AR) pathway rewiring, and immune/stromal changes under therapeutic pressure. Because metastatic CRPC often responds incompletely to immunotherapy and AR-directed treatment, cell-resolved analyses may help place putative drug-response factors within their tissue context. We examined whether secretory leukocyte protease inhibitor (SLPI), an epithelial secreted factor with immunoregulatory functions, is related to epithelial-state changes and enzalutamide response. Methods Public single-cell RNA-sequencing data from localized prostate cancer and metastatic CRPC (GSE274229) were analyzed using Seurat-based preprocessing, cell-type annotation, UCell pathway/state scoring, CellChat ligand-receptor inference, CopyKAT malignant-cell inference, Monocle2 trajectory analysis, hdWGCNA network analysis, and TCGA-PRAD clinical association analysis. SLPI was evaluated in 22Rv1 and C4-2 prostate cancer models using stable overexpression, qRT-PCR, proliferation, colony formation, migration, AR-pathway modulation, enzalutamide dose-response, and Annexin V/PI apoptosis assays. Results Progression to mCRPC was accompanied by altered epithelial-immune/stromal communication and shifts in inflammatory, extracellular-matrix, growth-factor, and immune-regulatory signaling. Putative malignant epithelial populations showed reduced AR-dependency and luminal-identity scores together with increased stress-adaptation and plasticity programs. Network and clinical association analyses highlighted SLPI as a progression-related epithelial factor with outcome relevance. In vitro, SLPI expression was lower in prostate cancer cells than in RWPE-1 cells, and SLPI overexpression suppressed proliferation, migration, and clonogenic growth. AR-pathway modulation showed reciprocal changes in SLPI expression: androgen deprivation and AR knockdown increased SLPI expression, whereas DHT-mediated AR reactivation reduced SLPI expression. SLPI overexpression enhanced enzalutamide-induced growth inhibition and apoptosis in the tested cell-line models. Conclusion These findings place SLPI at the intersection of AR-pathway state, epithelial adaptation, immune-context changes, and enzalutamide sensitivity in CRPC. SLPI may represent a therapy-response-associated epithelial factor in prostate cancer, but further protein-level, loss-of-function, in vivo, and clinically annotated validation will be required.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.